Joint Commission NPSG 3E

How does the Joint Commission's National Patient Safety Goal 3E affect your hospital?

	Learn how
Learn more about how VigiLanz can help your hospital with NPSG 3E and to schedule a live demo. Call: (773) 384-6420 E-mail: sales@vigilanzcorp.com Or fill out this form

"Anticoagulation is a high-risk treatment that commonly leads to adverse drug events due to the complexity of dosing anti-coagulation medications, monitoring their effects, and ensuring patient compliance with outpatient therapy. The use of standardized practices that include patient involvement can reduce the risk of adverse drug events associated with the use of heparin (unfractionated), low molecular weight heparin (LMWH), warfarin, and other anticoagulants."
--Joint Commission's Official Publication of the 2008 National Patient Safety Goals

NPSG 3E requires that, by January 1, 2009, all hospitals implement standardized systems to reduce the likelihood of patient harm associated with the use of anticoagulation therapy.

Are you going to be one of those struggling to meet the 3E requirements? Or will you blow past them?

	Listen now Listen to comments from VigiLanz user John Russillo, RPh, manager of clinical pharmacy services in the Hospital Operations Division of the John Muir Health System. He highlights how VigiLanz is used to comply with the Joint Commission on National Patient Safety Goal 3E. Using this system helped improve quality process at the patient level.

VigiLanz's Dynamic Monitoring System™ is a pharmacovigilance application that can take you far beyond the Joint Commission's standards to actually optimize your hospital's anti-coagulation strategy.

The VigiLanz Dynamic Monitoring System provides:

• Real time monitoring and alerts
• Automated renal dose tracking
• Trend tracking
• Heparin induced thrombocytopenia (HIT) monitoring
• Drug interaction reporting
• And anticipates and prevents ADEs caused by anti-coagulants

A comprehensive solution, such as the Dynamic Monitoring System, can bring your hospital into compliance with these new standards for inpatient and outpatient anticoagulation therapy management.

Full 3E implementation is required by January 1, 2009. Will you struggle to be compliant, or will you call VigiLanz?

For a demonstration of VigiLanz's Dynamic PharmacoVigilance (DPV) System® and how it can help you meet the Joint Commission's NPSG 3E, call us at (773) 384-6420 or send an e-mail to sales@vigilanzcorp.com.